I am a Pediatric and Adolescent Gynecologist, which combines my passion for gynecology with my love of working with children and young adults (and the people who care for them!). My approach to providing care is a collaborative one: my patients are individually unique and special, and their care should be tailored to be the best fit for them.
Prior to joining the Stanford faculty, I completed a fellowship in Pediatric and Adolescent Gynecology, From an academic standpoint, my current research focuses include: Gynecologic care for Oncology Survivors including Onco-Fertility and vulvovaginal graft-versus-host disease; gynecologic care of patients with Anorectal Malformations; Differences of Sex Development, Intersex conditions, and reproductive tract differences; and surgical care in pediatric gynecology.
- Adolescent and Pediatric Gynecology
- Obstetrics and Gynecology
Clinical Assistant Professor, Obstetrics & Gynecology - General
Site Principal Investigator, Differences of Sex Development - Translational Research Network (2021 - Present)
Assistant Fellowship Director, Pediatric and Adolescent Gynecology Fellowship Program (2021 - Present)
Medical Co-Director, LPCH clinic for Differences of Sex Development (2021 - Present)
Residency: Kaiser Permanente San Francisco Obstetrics and Gynecology Residency Program (2017) CA
Fellowship: Cincinnati Children's Hospital Pediatric and Adolescent Gynecology Fellowship (2019) OH
Board Certification: American Board of Obstetrics and Gynecology, Obstetrics and Gynecology (2018)
Medical Education: Case Western Reserve School of Medicine (2013) OH
Adolescents and long-acting reversible contraceptives: beyond the basics.
Current opinion in obstetrics & gynecology
The current article explores some of the more complex subtopics concerning adolescents and long-acting reversible contraceptives (LARC).Recent research has highlighted ways in which LARC provision can be optimized in adolescents and has identified gaps in adolescent LARC access and utilization.Contraceptive counseling for adolescents should be patient-centered, not necessarily LARC-first, to avoid coercion. There are increasing applications for the noncontraceptive benefits of LARC for several unique patient populations and medical conditions.
View details for DOI 10.1097/GCO.0000000000000668
View details for PubMedID 33002953
- Transgender Care in Adolescents Sanfilippo's Textbook of Gynecology CRC Press Taylor and Francis Group. 2020; 2: 265–272
- Gynecologic care for female patients with Fanconi Anemia Fanconi Anemia: Guidelines for Diagnosis and Management edited by Isis, S. Fanconi Anemia Research Fund. 2020; 5: 119–137
XY Gonadal Dysgenesis in a Phenotypic Female Identified by Direct-to-Consumer Genetic Testing.
2020; 146 (5)
We report a 16-year-old phenotypic female with 46,XY complete gonadal dysgenesis and metastatic dysgerminoma, unexpectedly discovered through direct-to-consumer (DTC) commercial genetic testing. This case underscores the importance of timely interdisciplinary care, including psychosocial intervention and consideration of gonadectomy, to optimize outcomes for individuals with differences of sex development. Her unique presentation highlights the implications of DTC genetic testing in a new diagnostic era and informs general pediatricians as well as specialists of nongenetic services about the value, capabilities, and limitations of DTC testing.
View details for DOI 10.1542/peds.2019-3302
View details for PubMedID 33060256
View details for PubMedCentralID PMC7875095
Pediatric and Young Adult Vulvovaginal Graft-versus-Host Disease
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
2019; 25 (12): 2408–15
Vulvovaginal graft-versus-host disease (GVHD) is an underdiagnosed and poorly recognized complication of hematopoietic stem cell transplantation (HSCT). Previous studies have reported findings restricted to predominantly adult populations. We report a case series of pediatric and young adult vulvovaginal GVHD, which was identified in 19 patients (median age, 11.8 years; range, 2.4 to 21.9 years) out of a total 302 female patients who underwent transplantation over an 8-year period at a pediatric HSCT center. The majority of patients had concomitant nongenital GVHD; only 1 patient had isolated vulvovaginal GVHD. The median time from bone marrow transplantation to diagnosis of vulvovaginal GVHD was 30 months (range, 2.3 to 97.5 months). A high percentage of the patients in our series were without vulvar or vaginal symptoms (n = 8; 42%), even though 17 patients (89%) presented with grade 3 disease based on current adult grading scales. Vulvar examination findings most frequently included interlabial and clitoral hood adhesions (89%), loss of architecture of the labia minora or clitoral hood (42%), and skin erosions or fissures (37%). Only 5 patients underwent a speculum exam, none of whom had vaginal GVHD. Examination findings of primary ovarian insufficiency (POI) can overlap with those of GVHD, and 6 patients (32%) in our cohort were diagnosed with POI. Only 1 patient was on systemic hormone replacement therapy at the time of vulvovaginal GVHD diagnosis. The majority of patients (n = 16) were treated with topical steroid therapy, with a median time to response of 43 days. Five patients (26%) had a complete response to therapy, and 10 patients (53%) had a partial response. This case series provides valuable insight into pediatric and young adult vulvovaginal GVHD and highlights the need for increased screening for vulvar disease in this population.
View details for DOI 10.1016/j.bbmt.2019.07.015
View details for Web of Science ID 000505855900012
View details for PubMedID 31325588
- Combined Chest and Pelvic Surgery for Transgender Patients in an Integrated Health Care Setting International Journal of Transgenderism 2017; 18: 382-8
- Preparing Future Physicians to Care for LGBT Patients: A Medical School Curriculum MedEdPORTAL Publications 2013
Risk factors for atherosclerosis and the development of preatherosclerotic intimal hyperplasia.
Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology
2007; 16 (6): 344–50
Intimal hyperplasia or thickening is considered to be the precursor lesion for atherosclerosis in humans; however, the factors governing its formation are unclear. To gain insight into the etiology of preatherosclerotic intimal hyperplasia, we correlated traditional risk factors for atherosclerosis with the intimal hyperplasia in an atherosclerosis-resistant vessel, the internal thoracic artery.Paired internal thoracic arteries were obtained from 89 autopsies. Multivariate logistic regression and multiple regression models were used to examine the association of preatherosclerotic intimal hyperplasia with traditional risk factors for atherosclerosis: age, gender, hypertension, smoking, body mass index, diabetes, and hypercholesterolemia.Atherosclerotic lesions consisting of fatty streaks and/or type III intermediate lesions were identified in 19 autopsies. Only age >75 years was found to be significantly correlated with atherosclerotic lesion development (P=.01). Multiple regression model of the intima/media ratio in all 89 cases revealed age >75 years (P<.0001), age 51-75 years (P=.0012), smoking (P=.008), and hypertension (P=.02) to be significantly correlated with intimal thickness. In the 70 cases without atherosclerosis, only age 51-75 years (P=.006) and smoking (P=.028) were found to be significantly associated with preatherosclerotic intimal thickening.In the atherosclerosis-resistant internal thoracic artery, preatherosclerotic intimal hyperplasia routinely forms during adulthood after the fourth decade and is associated with at least two traditional risk factors for atherosclerosis: age and smoking. These observations indicate that in some settings, intimal hyperplasia may be part of the disease process of atherosclerosis and that its formation may be influenced by traditional risk factors for atherosclerosis.
View details for DOI 10.1016/j.carpath.2007.05.007
View details for PubMedID 18005873
View details for PubMedCentralID PMC2185541
Regulation of protein kinase CK1alphaLS by dephosphorylation in response to hydrogen peroxide.
Archives of biochemistry and biophysics
2007; 466 (2): 242–49
Low levels of hydrogen peroxide (H(2)O(2)) are mitogenic to mammalian cells and stimulate the hyperphosphorylation of heterogeneous nuclear ribonucleoprotein C (hnRNP-C) by protein kinase CK1alpha. However, the mechanisms by which CK1alpha is regulated have been unclear. Here it is demonstrated that low levels of H(2)O(2) stimulate the rapid dephosphorylation of CK1alphaLS, a nuclear splice form of CK1alpha. Furthermore, it is demonstrated that either treatment of endothelial cells with H(2)O(2), or dephosphorylation of CK1alphaLS in vitro enhances the association of CK1alphaLS with hnRNP-C. In addition, dephosphorylation of CK1alphaLS in vitro enhances the kinase's ability to phosphorylate hnRNP-C. While CK1alpha appears to be present in all metazoans, analysis of CK1alpha genomic sequences from several species reveals that the alternatively spliced nuclear localizing L-insert is unique to vertebrates, as is the case for hnRNP-C. These observations indicate that CK1alphaLS and hnRNP-C represent conserved components of a vertebrate-specific H(2)O(2)-responsive nuclear signaling pathway.
View details for DOI 10.1016/j.abb.2007.06.010
View details for PubMedID 17626781
View details for PubMedCentralID PMC2131699